Comparing the current results to its competitors, Bolt Biotherapeutics Inc reported Revenue decrease in the 2 quarter 2026 year on year by -99.72 %, despite the revenue increase by the most of its competitors of 6.79 %, recorded in the same quarter.
April 25, 2025
: At the 2025 Annual Meeting of the American Association for Cancer Research (AACR), Bolt Biotherapeutics unveiled promising results from their Phase 1 dose-escalation clinical trial of BDC-3042. This investigational therapy shows notable potential for oncological interventions, having demonstrated a positive safety profile and an absence of dose-limiting toxicities up to a dosage level of 10 mg/kg administered biweekly. The findings underscore BDC-3042 s potential as a well-tolerated therapeutic candidate, warranting further exploration in subsequent clinical phases. The development of novel therapeutic agents continues to be a cornerstone of cancer research, with a focus on enhancing efficacy while mini...
New York-based law firm, Pomerantz LLP, has initiated an investigation into the claims made by investors of Bolt Biotherapeutics, Inc. (Bolt or the Company) (NASDAQ: BOLT). With rising concerns over potential misconduct or violations of regulatory obligations, shareholders are urged to contact Danielle Peyton, at newaction@pomlaw.com or 646-581-9980, ext. 7980, to participate in the investigation.
Bolt Biotherapeutics, a leading biotechnology company focused on developing innovative cancer therapies, is now facing scrutiny as Pomerantz LLP delves into ...
Bolt Biotherapeutics Initiates Phase 2 Study for BDC-1001 in HER2-Positive Breast Cancer Patients Previously Treated with Enhertu REDWOOD CITY, Calif., Dec. 05, 2023 - Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a leading biopharmaceutical company specializing in novel immunotherapies for cancer treatment, has announced the enrollment of the first patient in their Phase 2 clinical trial. This study aims to evaluate the efficacy and safety of BDC-1001, a HER2-targeting Boltbody Immune-Stimulating Antibody Conjugate (ISAC), either as a monotherapy or in combination with pertuzumab, another HER2-targeting antibody. Bolt Biotherapeutics decision to initiate this trial comes at a crucial time when in...
Janux Therapeutics Inc is a biotechnology company that focuses on developing and commercializing innovative cancer treatments. Their business model revolves around leveraging their expertise in immunotherapies and bispecific antibody platforms to create novel therapies that target tumor cells and activate the patient's immune system. By partnering with pharmaceutical companies and conducting clinical trials, they aim to bring effective and personalized cancer treatments to market.
Puma Biotechnology Inc operates as a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for the treatment of cancer. Their business model revolves around identifying promising preclinical and clinical drug candidates, conducting rigorous research and development, and seeking regulatory approval for their products. Puma Biotechnology Inc strives to effectively market and distribute their approved therapeutics to provide patients with potentially life-saving treatment options.
Zai Lab Limited operates as a biopharmaceutical company primarily in China. The company seeks to discover, develop, and commercialize innovative medicines to address unmet medical needs in the country. Zai Lab focuses on licensing and acquiring clinical stage or late-stage development drugs, and then progressing them through regulatory approval and commercial launch.
Xencor Inc is a biotechnology company that primarily focuses on the development of therapeutic antibodies. Their business model revolves around utilizing their proprietary XmAb® technology to engineer antibodies with enhanced properties for the treatment of various diseases. They collaborate with pharmaceutical companies to develop and commercialize these antibody therapeutics, generating revenue through upfront payments, milestone payments, and royalties.
MannKind Corporation is a biopharmaceutical company that focuses on the development and commercialization of inhaled therapeutic solutions for patients with diseases such as diabetes and pulmonary arterial hypertension. The company's business model revolves around conducting research and development to create innovative inhalation therapies and gaining regulatory approvals for these treatments. They then market and distribute their products, either directly or through partnerships, to healthcare providers and patients worldwide.
Sources:
Bolt Biotherapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Bolt Biotherapeutics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
